Sinopharm News - LARVOL Sigma

«1 234 5 6 7 8 9 10 11 12 13...224 225 »

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal: Selected Acute Safety Events Following the Use of Nirmatrelvir/Ritonavir or Molnupiravir for COVID-19: A Nationwide Cohort Study in South Korea. (Pubmed Central) - Oct 8, 2024
Overall, there were no increased risks of acute complications during and shortly after treatment with oral COVID-19 antivirals. Rather, the findings underscore their effectiveness in attenuating the risk of potential acute sequelae of COVID-19.

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Insights into the Main Protease of SARS-CoV-2: Thermodynamic Analysis, Structural Characterization, and the Impact of Inhibitors. (Pubmed Central) - Oct 8, 2024
The main protease (Mpro) of SARS-CoV-2 is an essential enzyme for coronaviral maturation and is the target of Paxlovid, which is currently the standard-of-care treatment for COVID-19...The overall energy landscape was obtained using variable temperature nanoelectrospray ionization (vT-nESI), thus providing quantitative evaluation of inhibitor binding on the stability of Mpro. Thermodynamic parameters extracted from van't Hoff plots revealed that the dimeric complexes containing each inhibitor showed enhanced stability through increased melting temperatures as well as overall lower average charge states, giving insight into the basis for inhibition mechanisms.

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Xevudy (sotrovimab) / GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases
Retrospective data, Journal, Real-world evidence, Real-world effectiveness, Real-world: Real-world effectiveness of early anti-SARS therapy in severely immunocompromised COVID-19 outpatients during the SARS-CoV-2 omicron variant era: a propensity score-adjusted retrospective cohort study. (Pubmed Central) - Oct 7, 2024
Thermodynamic parameters extracted from van't Hoff plots revealed that the dimeric complexes containing each inhibitor showed enhanced stability through increased melting temperatures as well as overall lower average charge states, giving insight into the basis for inhibition mechanisms. Early antiviral treatment was associated with a reduced risk of COVID-19-related hospitalization in ambulatory severely immunocompromised COVID-19 patients.

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: A Majority Of Americans Have No Or Low Awareness Of Paxlovid, The At-Home COVID-19 Treatment. (Pubmed Central) - Oct 7, 2024
Results suggest that Paxlovid underuse may be partly driven by a lack of effective public communication to generate awareness and knowledge about the drug, leading to low demand. As Paxlovid loses full government subsidies, further public outreach is needed to ensure that the public accesses it when needed.

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Xevudy (sotrovimab) / GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases
Clinical data, Retrospective data, Journal, Monotherapy: Does early combination vs. Monotherapy improve clinical outcomes of clinically extremely vulnerable patients with COVID-19? Results from a retrospective propensity-weighted analysis. (Pubmed Central) - Oct 5, 2024
Early combination therapy showed a favourable impact on a composite outcome (including mortality, hospitalizations and access to emergency department) in severely immunocompromised hosts who were all vaccinated. However, further studies are needed to support our results.

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer, bebtelovimab (LY-CoV1404) / AbCellera, Eli Lilly, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal: Reprint of: Evaluation of physicians prescribing of COVID-19 guideline-directed outpatient treatments in a primary care walk-in clinic. (Pubmed Central) - Oct 3, 2024
Nirmatrelvir-ritonavir was the most prescribed medication for the treatment of mild-to-moderate COVID-19, consistent with its position as first-line therapy and widespread accessibility. The study results will inform future educational opportunities, such as in-service presentations and handouts, that may improve the prescribing of outpatient treatment for mild-to-moderate COVID-19 moving forward.

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Prolonged course of Paxlovid administration in a centenarian with COVID-19: A case report. (Pubmed Central) - Oct 2, 2024
The study results will inform future educational opportunities, such as in-service presentations and handouts, that may improve the prescribing of outpatient treatment for mild-to-moderate COVID-19 moving forward. This case suggests that Paxlovid can be used cautiously in centenarians with renal insufficiency and two courses of treatment can be considered in patients with persistent positive nucleic acid.

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: The Latest Research About Paxlovid: Effectiveness, Access, and Possible Long COVID Benefits. (Pubmed Central) - Oct 1, 2024
This case suggests that Paxlovid can be used cautiously in centenarians with renal insufficiency and two courses of treatment can be considered in patients with persistent positive nucleic acid. No abstract available

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance. (Pubmed Central) - Sep 30, 2024
Thus, once treatment ends, if an effective adaptive immune response has not adequately developed, the remaining virus can lead to rebound. Our results provide insights into the mechanisms of rebound and can help develop better treatment strategies to minimize this possibility.

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Re: 'Nirmatrelvir/ritonavir treatment and risk for post-acute sequelae of COVID-19 in older Singaporeans' by Wee et al. (Pubmed Central) - Sep 29, 2024
Our results provide insights into the mechanisms of rebound and can help develop better treatment strategies to minimize this possibility. No abstract available

|||||||||| Comirnaty (tozinameran) / Pfizer, BioNTech, Covilo (BBIBP-CorV) / Wuhan Institute of Virology, Sinopharm
Journal: Predictors of Hospitalization in Breakthrough COVID-19 among Fully Vaccinated Individuals with Immune-Mediated Rheumatic Diseases: Data from SAFER-Study. (Pubmed Central) - Sep 29, 2024
The first booster (n = 150) was with BNT162b2 (BioNtech/Fosun Pharma/Pfizer) (63%) or ChAdOx1 (29%)...IMRD moderate/high activity (OR: 5.84; CI: 1.9-18.5; p = 0.002) and treatment with corticosteroids (OR: 2.94; CI: 1.02-8.49; p = 0.0043) were associated with higher odds of hospitalization, while increasing the number of vaccine doses was protective (OR: 0.37; CI: 0.15-0.9; p = 0.032). These findings, along with previous reassuring results about the safety of the COVID-19 vaccines, argue in favor of booster vaccination in IMRD patients.

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Myrtus communis L. Essential Oil Exhibits Antiviral Activity against Coronaviruses. (Pubmed Central) - Sep 29, 2024
Artificial bacterial chromosome plasmids that expressed SARS-CoV-2 used for replicon-to determine viral replication and viral assembly/egress on HEK293T/17 cells-and virus-like particles on Huh7.5-AT cells-to determine viral entry and assembly/egress-showed no antiviral activity with MEO in comparison to Remdesivir. This study reveals the potential effectiveness of MEO as an alternative natural remedy to treat human coronaviruses and a potential antiviral agent for future coronavirus infections.

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
STRATIFYING RISK FOR LONG COVID IN PATIENTS WITH IMMUNODEFICIENCY (Monitor 26; Hall A) - Sep 29, 2024 - Abstract #ACAAI2024ACAAI_1023;
Our study further suggests that Paxlovid could be an effective strategy in reducing the risk of PASC among immunodeficiency patients. Future prospective studies are necessary to confirm these findings.

||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, HEOR:  PROLIFIC: imPROving Quality of LIFe In the Long COVID Patient (clinicaltrials.gov) -  Sep 26, 2024
P2, N=180, Active, not recruiting,  Sponsor: Karolinska Institutet
Future prospective studies are necessary to confirm these findings. Recruiting --> Active, not recruiting | N=400 --> 180 | Trial completion date: Mar 2024 --> Nov 2024 | Trial primary completion date: Jan 2024 --> Nov 2024

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Identifying Veterans Who Benefit From Nirmatrelvir-Ritonavir: A Target Trial Emulation. (Pubmed Central) - Sep 26, 2024
Nirmatrelvir-ritonavir was effective in reducing 30-day hospitalization and death in older veterans, those at highest predicted risk for severe outcomes, and immunocompromised groups. Benefit was not observed in younger veterans or groups at lower predicted risk for hospitalization and death.

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal, Metastases: Nirmatrelvir and Ritonavir combination in COVID-19 patients with advanced chronic kidney disease. (Pubmed Central) - Sep 26, 2024
Benefit was not observed in younger veterans or groups at lower predicted risk for hospitalization and death. No abstract available

|||||||||| Covilo (BBIBP-CorV) / Wuhan Institute of Virology, Sinopharm
Journal, Real-world evidence, Real-world: A real-world study of BBIBP-CorV vaccine effectiveness in a Sri Lanka rural province. (Pubmed Central) - Sep 26, 2024
Individuals who have received two doses of the BBIBP-CorV vaccine are protected against hospitalisation, severe COVID-19 disease, and death. Duration of protection against hospitalisation, severe COVID-19, and fatal COVID-19 sustained at least 121 days, with no sign of waning during that time.

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Clinical, Journal: A SONAR report on Nirmatrelvir/ritonavir-associated rebound COVID-19: Using new databases for evaluating new diseases. (Pubmed Central) - Sep 25, 2024
Preprint services and Twitter facilitated identification of the largest case series of NM/R-associated COVID-19 rebound. The cases were reported in non-peer-reviewed media several weeks prior to the first peer-reviewed electronically disseminated publication of one person with this diagnosis.

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: SARS-CoV-2 Nirmatrelvir Resistance-A Concern for Immunocompromised Populations? (Pubmed Central) - Sep 25, 2024
The cases were reported in non-peer-reviewed media several weeks prior to the first peer-reviewed electronically disseminated publication of one person with this diagnosis. No abstract available

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Emerging SARS-CoV-2 Resistance After Antiviral Treatment. (Pubmed Central) - Sep 25, 2024
In this cohort study of 156 participants, treatment-emergent nirmatrelvir resistance mutations were commonly detected, especially in individuals who were immunosuppressed. However, these mutations were generally present at low frequencies and were transient in nature, suggesting a low risk for the spread of nirmatrelvir resistance in the community with the current variants and drug usage patterns.

|||||||||| Use of Outpatient Antiviral Therapy and Severe Outcomes from SARS-CoV-2 Omicron Infection in Patients with Immune Mediated Diseases on B Cell Depleting Agents (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1629;
In this observational cohort study of IMIDs patients with indications for anti-CD20 therapy, treatment with nirmatrelvir/ritonavir was associated with lower rates of hospitalization and death from COVID-19. Despite improved outcomes of SARS-CoV-2 infection during Omicron compared to prior epochs, patients receiving BCDT remain high risk for poor outcomes and should continue to be offered early outpatient treatment with nirmatrelvir/ritonavir.

|||||||||| Rituxan (rituximab) / Roche
Duration of SARS-CoV-2 Viral Shedding After Infection Among Patients with Rheumatic Disease Using Tumor Necrosis Factor Inhibitors or Rituximab (Room 143ABC; In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1420;
High rates of vaccination, uptake of antivirals, and prior exposure to COVID-19 may improve COVID-19 outcomes in this population, especially RTX users. Assessing the duration of viral culture positivity and differences in viral load are important next steps in this cohort.

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer, pomotrelvir (PBI-0451) / Pardes Biosci
Journal: Pomotrelvir and Nirmatrelvir Binding and Reactivity with SARS-CoV-2 Main Protease: Implications for Resistance Mechanisms from Computations. (Pubmed Central) - Sep 24, 2024
Analysis of the chemical reaction to form the covalent complex has shown a similar reaction mechanism and activation free energies for pomotrelvir, nirmatrelvir and C2. We hope that these findings could be useful to design better inhibitors to fight present and future variants of SARS-CoV-2 virus.

|||||||||| romlusevimab (BRII-198) / Brii Biosci, amubarvimab (BRII-196) / Brii Biosci
Retrospective data, Journal: Effect of amubarvimab-romlusevimab for treatment of severe COVID-19 in intensive care units: A retrospective cohort study. (Pubmed Central) - Sep 24, 2024
After including the above covariates, Multifactorial COX regression shows that the Amubarvimab - romlusevimab therapy(HR:0.392; CI:[0.211-0.729]; p:0.003), CRP, Lactate and PT-INR at admission are independent factors for mortality of severe COVID-19. Based on the current data, we conclude that amubarvimab-romlusevimab therapy is beneficial for patients with severe COVID-19.

|||||||||| Elayta (CT1812) / Cognition Therap
SHIMMER: Baseline Data and Early Lessons from the Ongoing Phase 2 Signal-finding Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies (DLB) () - Sep 24, 2024 - Abstract #CTAD2024CTAD_397;

||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
New trial:  COVID: Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients (clinicaltrials.gov) -  Sep 24, 2024
P=N/A, N=40, Not yet recruiting,  Sponsor: National Taiwan University Hospital

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Review, Journal: The Impact of Antidepressants on COVID-19 and Post-Acute COVID-19 Syndrome: A Scoping-Review Update (Pubmed Central) - Sep 23, 2024
In regions where neither vaccines nor antiviral agents currently approved for the prevention or treatment of COVID-19 are available, AD and in particular fluvoxamine would be a cost-effective alternative to protect against a severe course, even if this AD appears to have a smaller effect against COVID-19 than the currently approved antiviral agents, but with presumably better tolerability. A direct comparative clinical trial with approved antiviral agents is still pending and should be positive to further open the door for a guideline-based recommendation of fluvoxamine (or perhaps even AD) for COVID-19 or its aftermath.

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: A potential allosteric inhibitor of SARS-CoV-2 main protease (Mpro) identified through metastable state analysis. (Pubmed Central) - Sep 23, 2024
Anti-COVID19 drugs, such as nirmatrelvir, have been developed targeting the SARS-CoV-2 main protease, Mpro, based on the critical requirement of its proteolytic processing of the viral polyproteins into functional proteins essential for viral replication...Finally, we tested the three compounds in vitro using a BRET-based Mpro biosensor and found that one of the compounds (ZINC4497834) inhibited the Mpro activity. We envisage that the identification of a potential allosteric inhibitor of Mpro will aid in developing improved anti-COVID-19 therapy.

|||||||||| Journal: Identification of novel small-molecule inhibitors of SARS-CoV-2 by chemical genetics. (Pubmed Central) - Sep 23, 2024
Among them, four are nucleotide analogues (remdesivir, JT001, molnupiravir, and azvudine), while the other four are protease inhibitors (nirmatrelvir, ensitrelvir, leritrelvir, and simnotrelvir-ritonavir). In

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
PK/PD data, Journal: Target Attainment and Population Pharmacokinetics of Nirmatrelvir/Ritonavir in Critically Ill Adult Patients. (Pubmed Central) - Sep 23, 2024
Based on our dosing simulations, the initial dosage of NIR/RIT was 300mg/100mg twice a day in critically ill patients with CrCL>45 mL/min; When CrCL in critically ill patients is between 15 and 45 mL/min, NIR/RIT is 150mg/100mg twice a day. The maintenance dose is adjusted according to CrCL and AUC of RIT, with the dosages varying between 75mg/100mg and 300mg/100mg.

|||||||||| Rituxan (rituximab) / Roche
Rebound and Protracted COVID-19 in Patients Receiving Rituximab for Autoimmune and Glomerular Diseases (Exhibit Hall, Convention Center) - Sep 23, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_1160;
COVID-19 in B cell-depleted patients is associated with high rates of rebounding disease and hospitalization despite available treatments and vaccines. IVIG is effective as an adjunct strategy.

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Treatment of persistent coronavirus disease 2019 (COVID-19) in a B cell acute lymphoblastic leukemia patient with using nirmatrelvir/ritonavir extended course: A case report. (Pubmed Central) - Sep 21, 2024
Patients with hematological malignancies are at increased risk of persistent coronavirus disease 2019 (COVID-19) infection, a unique clinical condition, for which the optimal treatment is unknown. Here we report a case of persistent COVID-19 in acute lymphoblastic leukemia (ALL) patient who successfully responded to extended course nirmatrelvir/ritonavir.

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Clinical, Retrospective data, Review, Journal: Paxlovid for the treatment of COVID-19: a systematic review and meta-analysis. (Pubmed Central) - Sep 20, 2024
Here we report a case of persistent COVID-19 in acute lymphoblastic leukemia (ALL) patient who successfully responded to extended course nirmatrelvir/ritonavir. Paxlovid can be considered an effective therapeutic agent for treating patients with COVID-19.

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Comprehensive Analysis of Omicron Subvariants: EG.5 Rise, Vaccination Strategies, and Global Impact. (Pubmed Central) - Sep 20, 2024
In the context of the evolving variants, the FDA has granted emergency use authorization for updated COVID-19 vaccines targeting circulating strains, reflecting the adaptability of vaccination strategies to address emerging challenges. This comprehensive overview provides a nuanced understanding of the diverse Omicron subvariants, their global impact, and the ongoing efforts to combat their spread through vaccination and therapeutic interventions.

|||||||||| Evusheld (cilgavimab/tixagevimab) / AstraZeneca, Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal, CAR T-Cell Therapy: Protracted coronavirus disease 2019 after chimeric antigen receptor-T cell therapy successfully treated with sequential multidrug therapy. (Pubmed Central) - Sep 20, 2024
The patient was diagnosed with protracted COVID-19 and was treated with remdesivir, molnupiravir, nirmatrelvir/ritonavir, and tixagevimab/cilgavimab. These treatments appeared to contribute to the improvement of protracted COVID-19.

||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Enrollment closed, Trial completion date, Trial primary completion date:  RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms (clinicaltrials.gov) -  Sep 19, 2024
P2, N=964, Active, not recruiting,  Sponsor: Kanecia Obie Zimmerman
These treatments appeared to contribute to the improvement of protracted COVID-19. Recruiting --> Active, not recruiting | Trial completion date: Oct 2025 --> Mar 2025 | Trial primary completion date: Jul 2025 --> Dec 2024

||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Trial completion:  PAXLC: A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID. (clinicaltrials.gov) -  Sep 18, 2024
P2, N=100, Completed,  Sponsor: Harlan M Krumholz
Recruiting --> Active, not recruiting | Trial completion date: Oct 2025 --> Mar 2025 | Trial primary completion date: Jul 2025 --> Dec 2024 Active, not recruiting --> Completed

||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Enrollment closed, Trial completion date, Trial primary completion date:  RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms (clinicaltrials.gov) -  Sep 18, 2024
P2, N=964, Active, not recruiting,  Sponsor: Kanecia Obie Zimmerman
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Oct 2025 --> Mar 2025 | Trial primary completion date: Jul 2025 --> Dec 2024

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal: Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection. (Pubmed Central) - Sep 18, 2024
This study supports the use of direct-acting antivirals (DAAs) for late-onset management of persistent SARS-CoV-2 infection in immunocompromised hosts. However, treatment courses likely require to be extended for maximal therapeutic benefit, calling for appropriately powered clinical trials to meet the specific needs of this patient group.

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal: Comparing the effectiveness of molnupiravir and nirmatrelvir-ritonavir in non-hospitalized and hospitalized COVID-19 patients with type 2 diabetes: A target trial emulation study. (Pubmed Central) - Sep 18, 2024
However, treatment courses likely require to be extended for maximal therapeutic benefit, calling for appropriately powered clinical trials to meet the specific needs of this patient group. The use of nirmatrelvir-ritonavir may be preferred to molnupiravir for COVID-19 patients with T2DM and without contraindication to either treatment.

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Xocova (ensitrelvir) / Shionogi
Journal: A comprehensive study of SARS-CoV-2 mfigain protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system. (Pubmed Central) - Sep 17, 2024
Moreover, we showed the putative molecular mechanism of resistance based on in silico molecular modelling. These findings have implications on the development of future generation Mpro inhibitors, will help to understand SARS-CoV-2 protease inhibitor resistance mechanisms and show the relevance of specific mutations, thereby informing treatment decisions.

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal: Drug susceptibility and the potential for drug-resistant SARS-CoV-2 emergence in immunocompromised animals. (Pubmed Central) - Sep 17, 2024
Viruses isolated from drug-treated immunocompromised hamsters did not show reduced susceptibility to the drugs. Molnupiravir and nirmatrelvir remain effective in

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Preclinical, Journal: Nirmatrelvir and Molnupiravir maintain potent in vitro and in vivo antiviral activity against circulating SARS-CoV-2 Omicron subvariants. (Pubmed Central) - Sep 17, 2024
In this study, we evaluated the efficacy of nirmatrelvir (PF-07321332) and other clinically significant SARS-CoV-2 antivirals against a diverse panel of SARS-CoV-2 variants, encompassing the newly identified Omicron subvariants XBB1.5 and JN.1, using live-virus antiviral assays. Our findings demonstrate that while the last Omicron subvariants exhibited heightened pathogenicity in our animal model, nirmatrelvir and other clinically relevant antivirals consistently maintained their efficacy against all tested variants, including the XBB1.5 subvariant.

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Nirmatrelvir/ritonavir standby treatment for International Travelers: CON (Convention Center - Room 353 (3rd Floor); In-Person-Only) - Sep 15, 2024 - Abstract #ASTMH2024ASTMH_422;

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Nirmatrelvir/ritonavir standby treatment for International Travelers: PRO (Convention Center - Room 353 (3rd Floor); In-Person-Only) - Sep 15, 2024 - Abstract #ASTMH2024ASTMH_421;

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
66 - Clinical Tropical Medicine Debates: COVID and Cholera Vaccines (Convention Center - Room 353 (3rd Floor); In-Person-Only) - Sep 15, 2024 - Abstract #ASTMH2024ASTMH_420;
This symposium will explore the use of Nirmatrelvir/ritonavir for standby treatment of COVID in international travelers and expanded use of vaccines for prevention of Cholera in a debate style format. Presenters will articulate a pro or con position around each issue followed by a panel discussion of the merits of each argument.

|||||||||| GC376 / Anivive, Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Xocova (ensitrelvir) / Shionogi
Journal: SARS-CoV-2 Mpro inhibitor identification using a cellular gain-of-signal assay for high-throughput screening. (Pubmed Central) - Sep 15, 2024
Presenters will articulate a pro or con position around each issue followed by a panel discussion of the merits of each argument. The SARS2 main protease enzyme, Mpro (also called 3C-like protease, 3CLpro), is a bona fide drug target as evidenced by potent inhibition with nirmatrelvir and ensitrelvir, the active components of the drugs Paxlovid and Xocova, respectively...In this assay, Mpro inhibits expression of a luciferase reporter, and 8,777 small molecules were considered hits by causing a gain in luciferase activity 3x SD above the sample field activity (6.8% gain-of-signal relative to 100

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal: Molnupiravir or nirmatrelvir-ritonavir reduce the likelihood of hospitalization and mortality in immunocompromised patients with Covid-19. (Pubmed Central) - Sep 13, 2024
The SARS2 main protease enzyme, Mpro (also called 3C-like protease, 3CLpro), is a bona fide drug target as evidenced by potent inhibition with nirmatrelvir and ensitrelvir, the active components of the drugs Paxlovid and Xocova, respectively...In this assay, Mpro inhibits expression of a luciferase reporter, and 8,777 small molecules were considered hits by causing a gain in luciferase activity 3x SD above the sample field activity (6.8% gain-of-signal relative to 100 No abstract available

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Nirmatreolvir-ritonavir (Paxlovid) leads to no reduction of symptoms or hospitalizations in vaccinated or unvaccinated high-risk adults with Covid-19. (Pubmed Central) - Sep 13, 2024
No abstract available No abstract available

|||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Retrospective data, Journal: Effectiveness of Paxlovid in the treatment of the SARS-CoV-2 Omicron variant infection in children with hematologic malignancies: a retrospective cohort study. (Pubmed Central) - Sep 12, 2024
No factor was found to be statistically significant in predicting re-positive test results based on the binary logistic regression analysis. Administering Paxlovid within 5 days of the diagnosis of the SARS-CoV-2 Omicron variant infection in children may effectively shorten the clearance time of the virus, but there is still the possibility the patients may have re-positive test results.



	Diseases Companies Products Productz Mechanisms of Action Sites